Cocrystal Pharma, Inc.
COCP
$1.04
$0.032.97%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 954.00K | 1.12M | 1.36M | 2.04M | 3.24M |
| Gross Profit | -954.00K | -1.12M | -1.36M | -2.04M | -3.24M |
| SG&A Expenses | 1.14M | 986.00K | 981.00K | 1.19M | 1.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.09M | 2.11M | 2.34M | 3.23M | 5.04M |
| Operating Income | -2.09M | -2.11M | -2.34M | -3.23M | -5.04M |
| Income Before Tax | -2.05M | -2.06M | -2.30M | -3.27M | -4.94M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.05M | -2.06M | -2.30M | -3.27M | -4.94M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.05M | -2.06M | -2.30M | -3.27M | -4.94M |
| EBIT | -2.09M | -2.11M | -2.34M | -3.23M | -5.04M |
| EBITDA | -2.08M | -2.09M | -2.32M | -3.20M | -5.01M |
| EPS Basic | -0.19 | -0.20 | -0.23 | -0.32 | -0.49 |
| Normalized Basic EPS | -0.12 | -0.13 | -0.14 | -0.20 | -0.30 |
| EPS Diluted | -0.19 | -0.20 | -0.23 | -0.32 | -0.49 |
| Normalized Diluted EPS | -0.12 | -0.13 | -0.14 | -0.20 | -0.30 |
| Average Basic Shares Outstanding | 10.99M | 10.17M | 10.17M | 10.17M | 10.17M |
| Average Diluted Shares Outstanding | 10.99M | 10.17M | 10.17M | 10.17M | 10.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |